CVRx Inc. (NASDAQ: CVRX) announced that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. The Minneapolis-based medical device company said this represents the first coverage policy for its heart failure treatment.

Humana operates the second largest Medicare Advantage program in the United States, providing coverage to approximately 5.2 million Medicare Advantage members across 46 states. The new policy covers Barostim for patients meeting its current FDA-approved indication and patients enrolled in the BENEFIT-HF trial, a heart failure study evaluating the therapy in an expanded patient population.

Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery wall. The FDA has approved the technology for heart failure patients in the United States, and it has received CE Mark approval for heart failure and resistant hypertension in the European Economic Area.

The coverage policy follows two other reimbursement developments for Barostim this year. Category I CPT codes for the Barostim procedure became effective January 1, 2026. The Centers for Medicare & Medicaid Services also approved Category B IDE coverage for patients enrolled in the BENEFIT-HF trial that same month.

"We are pleased to receive this Medicare Advantage coverage policy from Humana, which represents the first coverage policy for Barostim and marks an important milestone in our efforts to expand access to the therapy for patients living with heart failure," said Kevin Hykes, President and Chief Executive Officer of CVRx.

The information is based on a company press release statement.